BioCentury
ARTICLE | Finance

Amolyt pockets $80M series B to push peptides further into clinic

September 16, 2021 6:32 PM UTC

Amolyt has again attracted a syndicate of top-tier investors to advance its pipeline of peptide therapies for rare endocrine diseases, this time adding $80 million in a series B round.

Two years ago, Amolyt Pharma S.A.S. — then known as Alizé Pharma 3 — raised the second-largest European series A round of 2019 at $74.5 million. New investors Andera Partners and Sectoral Asset Management have now co-led the series B round to push Amolyt’s lead program through clinical proof-of-concept...